A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis

Increased concentrations of interleukin (IL)-1α have been recently described in tissues of patients with systemic sclerosis (SSc) suggesting that IL-1α inhibition may be a target for treatment. We conducted a double-blind, placebo-controlled study to assess the safety and efficacy of the fully human...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomonidi, Nicky, Vlachoyiannopoulos, Panayiotis G., Pappa, Maria, Liantinioti, Georgia, Ktena, Sofia, Theotikos, Evangelos, Elezoglou, Antonia, Netea, Mihai G., Giamarellos-Bourboulis, Evangelos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481358/
https://www.ncbi.nlm.nih.gov/pubmed/37680472
http://dx.doi.org/10.1016/j.isci.2023.107670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481358/
https://www.ncbi.nlm.nih.gov/pubmed/37680472
http://dx.doi.org/10.1016/j.isci.2023.107670

Ejemplares similares